Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Antibodies: Co-existence

The battle for the now-hot antibody market is being fought on two fronts: among competing transgenic mouse technologies for human antibody production, and between those mice and older technologies including phage display and antibody humanization.

For the increasingly popular human antibody companies, the challenge is to manage an over-abundance of riches, both in terms of targets and partners, while adding technologies that make the mice even more useful. For humanized antibody developers, the challenge is getting investors to remember that the companies have rich pipelines of products at all stages of development, and that there appears to be no clinical difference between the two types of antibodies.

Of mice and MEDX

Medarex Inc. is looking to strengthen its human antibody technology portfolio. By in-licensing Kirin Brewery Co. Ltd.'s transchromosomic-mice (TC mice), MEDX hopes not only to gain a larger share of

Read the full 1380 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE